AIPLA Comments on FDA Biosimilars Draft Guidances

May 24, 2012

File Downloads

All documents are in PDF format.

While the Food and Drug Administration’s role in the scientific regulation of biologic drugs is generally outside this primary interest, implementation of the new abbreviated regulatory pathway for biosimilar products authorized under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) contains some aspects that impact intellectual property rights, including patents, trademarks, trade secrets, regulatory exclusivity, and IP litigation.

In view of this impact, AIPLA provides comments on those aspects of the Draft Guidances that more or less directly impact intellectual property rights, and therefore impact our membership. Specifically, AIPLA provides comments on three issues: (1) definition of “protein (except any chemically synthesized polypeptide)”; (2) molecules having a changed amino acid sequence compared with the reference product; and (3) publication of exclusivity expiration dates.

Current Status

 

Upcoming Events

  • AIPLA 2025 Annual Meeting

    October 30 to November 1, 2025

    Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2025 Annual meeting will take place at the Westin Washington, DC, Downtown. Leadership Meetings on Wednesday, October 29. Programming scheduled October 30 - November 1.
  • 2026 Spring Meeting - San Francisco, CA

    May 13 to 15, 2026

    We’re excited to welcome you to the 2026 AIPLA Spring Meeting, where innovation, technology, and intellectual property come together to shape the future. San Francisco is ready for your ideas, energy, and passion for IP!
  • AIPLA 2026 Annual Meeting

    October 29 to 31, 2026

    Join us as we bring IP professionals together to learn and connect. More information coming soon! The 2026 Annual meeting will take place at the Westin Washington, DC, Downtown. Leadership Meetings on Wednesday, October 28. Programming scheduled October 29 - 31.